MBL77 - AN OVERVIEW

Other than ibrutinib, clients with M-CLL, devoid of TP53 aberrations and suit ample to tolerate FCR therapy, should still be very good candidates for that latter, with the gain getting this procedure is usually done in six months even though ibrutinib must be taken indefinitely. This option could well be particularly important for non-compliant suf